Anika Therapeutics (ANIK) Common Equity (2016 - 2025)
Historic Common Equity for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $146.8 million.
- Anika Therapeutics' Common Equity fell 1838.0% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.8 million, marking a year-over-year decrease of 1838.0%. This contributed to the annual value of $154.0 million for FY2024, which is 2745.44% down from last year.
- According to the latest figures from Q3 2025, Anika Therapeutics' Common Equity is $146.8 million, which was down 1838.0% from $147.7 million recorded in Q2 2025.
- Anika Therapeutics' Common Equity's 5-year high stood at $290.1 million during Q3 2021, with a 5-year trough of $146.8 million in Q3 2025.
- Its 5-year average for Common Equity is $237.5 million, with a median of $274.0 million in 2023.
- Per our database at Business Quant, Anika Therapeutics' Common Equity skyrocketed by 539.1% in 2021 and then plummeted by 3350.34% in 2024.
- Quarter analysis of 5 years shows Anika Therapeutics' Common Equity stood at $287.1 million in 2021, then dropped by 0.53% to $285.6 million in 2022, then fell by 25.67% to $212.3 million in 2023, then dropped by 27.45% to $154.0 million in 2024, then decreased by 4.67% to $146.8 million in 2025.
- Its Common Equity was $146.8 million in Q3 2025, compared to $147.7 million in Q2 2025 and $148.4 million in Q1 2025.